Reliance Global Group (EZRA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
12 Mar, 2026Executive summary
The annual meeting is scheduled for April 29, 2026, with voting on five key proposals, including director elections, auditor ratification, equity plan amendment, share issuance under a purchase agreement, and adjournment authority.
The Board unanimously recommends voting in favor of all proposals and outlines procedures for proxy voting, revocation, and quorum requirements.
Stockholders of record as of March 5, 2026, are eligible to vote, with 21,253,013 shares outstanding, each entitled to one vote.
Voting matters and shareholder proposals
Election of five directors for one-year terms expiring at the 2027 annual meeting.
Ratification of Urish Popeck & Co., LLC as independent auditor for fiscal year ending December 31, 2026.
Amendment to the 2025 Equity Incentive Plan to increase authorized shares by 14,000,000.
Approval of share issuance under a $50 million equity line of credit with White Lion Capital, exceeding Nasdaq's 20% rule.
Adjournment proposal to allow the Board to adjourn the meeting if necessary for further proxy solicitation.
Board of directors and corporate governance
Board consists of five members with diverse backgrounds in finance, insurance, and business management.
Three standing committees: Audit, Compensation, and Nominating & Governance, each composed of independent directors.
Board leadership structure combines Chairman and CEO roles for efficiency given company size.
Code of Ethics and Business Conduct applies to all employees, officers, and directors.
Latest events from Reliance Global Group
- Net loss improved to $1.4M as insurance growth and tech/life sciences investments advanced.EZRA
Q1 20268 May 2026 - All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 20266 May 2026 - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 20256 May 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing4 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and major share issuance.EZRA
Proxy filing23 Mar 2026 - Q2 net loss improved 62%, Spetner deal to double revenue and boost profitability.EZRA
Q2 20242 Feb 2026 - Raising $5.3M for growth, tech, and digital assets amid dilution and Nasdaq compliance risks.EZRA
Registration Filing23 Jan 2026 - Q3 2024 delivered revenue growth, cost cuts, positive Adjusted EBITDA, and major M&A and tech moves.EZRA
Q3 202415 Jan 2026 - Revenue up 2%, net loss down 24%, and tech advances set stage for further growth.EZRA
Q4 202426 Dec 2025